Thailand population

An aging population is intensifying global healthcare demand and EZZ’s life science brands are already premium solutions

EZZ capitalizes on an increasing focus on the life sciences sector as an aging global population places high demands on health and wellness.

Genomic Technology Company, EZZ Life Science Holdings (ASX:EZZ) seizes opportunities in the life sciences sector, which is one of the fastest growing industries in the world.

Life sciences covers a wide range of businesses ranging from research, development and manufacturing of pharmaceuticals, biotechnology-based foods, medical devices, biomedical technologies, nutraceuticals, cosmeceuticals, processing of food and other products.

EZZ Chairman and Non-Executive Director Glenn Cross said Stockhead the COVID-19 pandemic has raised the profile of the life sciences sector.

Cross has over 40 years of experience in the life sciences industry nationally and internationally, including approximately 20 years in senior management positions. He was the former CEO and COO of AusBiotech – Australia’s biotech organization.

“The pandemic has shown many people how important your health is, the importance of taking care of your health and well-being, and the role of the life sciences industry,” Cross said.

“There is a much greater emphasis on health, well-being and the quality of products used in the healthcare industry worldwide.”

Innovations across the sector — from vaccines to treatments — have already changed our lives in the time of COVID-19, he says.

“There would still be a lot of the world in shutdowns and destroyed trade globally and we would be in for a big mess,” Cross said.

“The industry’s ability to produce vaccines and therapies in unprecedented timeframes has made many people more familiar with the industry.”

Strong growth projections

The life sciences sector has experienced significant growth. At the end of 2020, the total global pharmaceutical market was valued at approximately US$1.27 trillion. This is a significant increase from 2001, when the market was valued at around $390 billion.

The size of the global biotechnology market was approximately $449 billion in 2020 and is expected to reach $727 billion annually by 2025, while the global medical device business was valued at $456 billion in 2019 .

Discoveries of new diseases combined with the strong desire of an aging population to live longer and enjoy a better quality of life as they age are drawing more and more attention to the life sciences sector. .

EZZ strives to become one of the leading life science companies in Australia and New Zealand. His primary focus has been genomic health and the development of a product portfolio of genomic research-based healthcare solutions.

EZZ is focusing its genomics research and product development to isolate and unpack four key areas, including:

The company offers dietary supplements, natural foods and probiotics as well as skin care products under two brands, EZZ and EAORON respectively.

EZZ and EAORON products are sold in pharmacies, supermarkets and specialist retailers in Australia and New Zealand.

Southeast Asia is a key target for expansion, with Singapore and China already distributing its products, with negotiations underway with potential distributors in Malaysia.

The company also sees opportunities in Thailand, Vietnam, the Philippines and Indonesia.

Sales from our flagship stores on Tmall Global – China’s largest cross-border B2C online marketplace have generated $11 million in revenue since its launch in August 2020.

EZZ is expanding to other major e-commerce platforms in mainland China, as well as through online and offline distribution channels in Hong Kong and Taiwan.

Greater awareness of TGA

Cross said the Therapeutics Goods Administration (TGA) has grown in prominence since the pandemic.

The TGA is part of the Australian Department of Health and is responsible for regulating therapeutic products including prescription drugs, vaccines, sunscreens, vitamins and minerals, medical devices, blood and blood products.

“Three years ago, if you asked 10 people on the street what TGA was, probably eight of them would have had no idea,” Cross said.

“So in terms of focusing on regulatory scrutiny and approving the quality products that people put into their bodies, then the pandemic has certainly highlighted that to a large extent in the general population.”

Cross said Australia’s TGA has a strong reputation as one of the world’s leading regulators.

“The FDA in the US is probably the most recognized, but the TGA is up there with regulators in Canada, the UK, Japan, France and Germany as one of the best in the world” , did he declare.

“He is there to ensure that the products he registers are safe, made with quality components and under quality conditions.

“It also ensures that what the manufacturers and distributors say their products can do has been verified and finally they have post-compliance monitoring to make sure nothing happens with the product over a period of time.”

Importance of TGA Approval

Cross said almost all EZZ products are TGA approved so people can rest assured that they have been checked and manufactured to high quality standards.

“Key EZZ products are registered by the TGA under the ARTG (Australian Register of Therapeutic Goods),” Cross said.

“Our products have all been made under good manufacturing practice and the ingredients have all been checked by the regulator and we have permission to sell our products in Australia – and make the claims we do on our packaging and brochures .

Cross said the focus on TGA endorsement and high quality was one of the reasons he joined EZZ.

“My background has been in regulated products at all levels, including diagnostics, drugs and medical devices, so I was very comfortable with EZZ complying with these regulatory terms and standards” , did he declare.

Focus on R&D and manufacturing

EZZ has entered into local and international university partnerships to boost research on human papillomavirus and genetic longevity.

“We have a strong R&D program with Auckland University of Technology and are actively researching new products that strategically fit EZZ,” he said.

It also planned to establish a Good Manufacturing Practice (GMP) certified manufacturing facility in Australia or New Zealand to improve production efficiency..

“We are actively and fully intend to have a GMP facility by the end of 2022,” he said.

“We are on the acquisition trail and plan to expand our product line.”

This article was developed in conjunction with EZZ, a Stockhead advertiser at the time of publication.

This article does not constitute advice on financial products. You should consider obtaining independent advice before making any financial decisions.

You may be interested in